Monoclonal antibody
Type ?
Source Humanized
Target CGRPR
Clinical data
ATC code None
Legal status
Legal status
  • Investigational
CAS Number 1644539-04-7

ALD403 is an experimental drug being developed by Alder Biopharmaceuticals for the treatment of migraine. It is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP) as an antagonist.[1] It is currently in Phase III clinical trials.[2]


  1. Dodick, David W; Goadsby, Peter J; Silberstein, Stephen D; Lipton, Richard B; Olesen, Jes; Ashina, Messoud; Wilks, Kerri; Kudrow, David; Kroll, Robin; Kohrman, Bruce; Bargar, Robert; Hirman, Joe; Smith, Jeff (2014). "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial". The Lancet Neurology. 13 (11): 1100. doi:10.1016/S1474-4422(14)70209-1. PMID 25297013.
  2. "Pipeline". Alder Biopharmaceuticals.

This article is issued from Wikipedia - version of the 9/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.